

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC., TEVA PHARMACEUTICALS USA,
INC. and AKORN INC.,¹
Petitioners,

v.

ALLERGAN, INC.
Patent Owner.

Case IPR2016-01127 (8,685,930 B2)
Case IPR2016-01128 (8,629,111 B2)
Case IPR2016-01129 (8,642,556 B2)
Case IPR2016-01130 (8,633,162 B2)
Case IPR2016-01131 (8,648,048 B2)
Case IPR2016-01132 (9,248,191 B2)

**PETITIONER MYLAN PHARMACEUTICALS INC.'S MANDATORY
CHANGE-OF-INFORMATION NOTICES**

¹ Cases IPR2017-00576 and IPR2017-00594, IPR2017-00578 and IPR2017-00596, IPR2017-00579 and IPR2017-00598, IPR2017-00583 and IPR2017-00599, IPR2017-00585 and IPR2017-00600, and IPR2017-00586 and IPR2017-00601, have respectively been joined with the captioned proceedings. The word-for-word identical paper is filed in each proceeding identified in the caption pursuant to the Board's Scheduling Order (Paper 10).

Pursuant to 37 C.F.R. § 42.8(a)(3), the undersigned on behalf of and acting in a representative capacity for Petitioner Mylan Pharmaceuticals Inc. (“Mylan”), hereby submits the following mandatory change-of-information notices in connection with the *inter partes* reviews identified in the caption.

A. Real Party-In-Interest (37 C.F.R. § 42.8(b)(1)) – Unchanged

B. Related Matters (37 C.F.R. § 42.8(b)(2)) – Revised

Allergan, Inc. v. Teva Pharm. USA, Inc., No. 2018-1130 (Fed. Cir.)
(invalidity affirmed November 13, 2018) (EX1163-65; EX1172);

Allergan, Inc. v. Deva Holding A.S., No. 2:16-cv-1447 (E.D. Tex.) (filed December 22, 2016);

Allergan, Inc. v. Saptalis Pharmaceuticals, LLC, No. 1:18-cv-01231 (D. Del.) (filed August 10, 2018);

Allergan, Inc. v. Amneal Pharmaceuticals LLC, No. 1:18-cv-01457 (D. Del.) (filed September 20, 2018);

St. Regis Mohawk Tribe v. Mylan Pharmaceuticals Inc., No. 2018-1638 (Fed. Cir.) (stay pending petition for certiorari denied November 13, 2018).

U.S. Patent Application No. 15/585,320 (filed May 3, 2017).

C. Lead and Back-up Counsel (37 C.F.R. § 42.8(b)(3)) – Unchanged

D. Electronic Service – Unchanged

Respectfully submitted,

Dated: November 21, 2018

/ Steven Parmelee /

Steven W. Parmelee

Reg. No. 31,990

CERTIFICATE OF SERVICE

This is to certify that I caused to be served a true and correct copy of the foregoing Petitioner Mylan Pharmaceuticals Inc.'s Mandatory Change-of-Information Notices on this 21th day of November, 2018, on the Patent Owner at the correspondence address of Allergan, Inc. and St. Regis Mohawk Tribe as follows:

Dorothy P. Whelan
Michael Kane
Susan Morrison Colletti
Robert M. Oakes
Jonathan Singer
Fish & Richardson P.C.
3200 RBC Plaza
60 South Sixth Street
Minneapolis, MN 55402
Email: IPR13351-0008IP1@fr.com
Email: IPR13351-0008IP2@fr.com
Email: IPR13351-0008IP3@fr.com
Email: IPR13351-0008IP4@fr.com
Email: IPR13351-0008IP5@fr.com
Email: IPR13351-0008IP6@fr.com
Email: PTABInbound@fr.com

Alfonso Chan
Joseph DePumpo
Michael W. Shore
Christopher L. Evans
Shore Chan DePumpo LLP
901 Main Street, Suite 3300
Dallas, TX 75201
Email: achan@shorechan.com
Email: jdepumpo@shorechan.com
Email: mshore@shorechan.com
Email: cevans@shorechan.com

And on the remaining petitioners as follows:

Gary Speier
Mark Schuman
CARLSON, CASPERS, VANDENBURGH,
LINDQUIST & SCHUMAN, P.A.
225 South Sixth Street, Suite 4200
Minneapolis, MN 55402
Email: gspeier@carlsoncaspers.com
Email: mschuman@carlsoncaspers.com
Attorneys for Teva Pharmaceuticals USA, Inc.

Michael Dzwonczyk
Azadeh Kokabi
Travis Ribar
SUGHRUE MION, PLLC
2100 Pennsylvania Ave., NW
Washington, DC 20037
Email: mdzwonczyk@sughrue.com
Email: akokabi@sughrue.com
Email: tribar@sughrue.com
Attorneys for Akorn Inc.

Respectfully submitted,

Dated: November 21, 2018

/ Steve Parmelee /

Steven W. Parmelee, Lead Counsel
Reg. No. 31,990